Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAcute LeukemiasMyeloproliferative neoplasms (MPN) and myelodysplastic neoplasms (MDS)TransplantationDiseaseAcute Lymphoblastic LeukaemiaAcute Myeloid LeukemiaChronic Myeloid LeukemiaMyelodysplastic NeoplasmsStem Cell Transplantation, AllogeneicSubgroupFLT3 mutationHigh riskMDS with elevated blasts -2ICD10C91.0-C92.0-C92.1-C92.5-C92.6-C92.7-C92.8-C92.9-C93.0-D46.-MeSHHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteMyelodysplastic SyndromesPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaTransplantation ConditioningSequenceAMLSG 31-19/HOVON 501DAUN60/CYTA200/MDST50, AML Ind. (PID1079) -|- Cons. (PID1080) -|- maint. (PID1081)ChemotherapyChemo-substanceAzacitidineCyclophosphamideCytarabineDaunorubicinGlasdegibLenalidomideMelphalanMidostaurinVenetoclaxChemo-substanceAzacitidineCyclophosphamideCytarabineDaunorubicinGlasdegibLenalidomideMelphalanMidostaurinVenetoclaxChemo-substanceAzacitidineCyclophosphamideCytarabineDaunorubicinGlasdegibLenalidomideMelphalanMidostaurinVenetoclaxChemo-substanceAzacitidineCyclophosphamideCytarabineDaunorubicinGlasdegibLenalidomideMelphalanMidostaurinVenetoclaxNo. Substances123 RadiotherapySupportive therapySupportive substanceAllopurinolAnti-thymocyte Globulin (Rabbit)Balanced Crystalloid SolutionBusulfanCarmustineCiprofloxacinCotrimoxazoleDexamethasoneDimetindenEtoposide phosphateFilgrastimFluconazoleFludarabineFosaprepitantFurosemideGranisetronLevetiracetamMelphalanMesnaMethylprednisoloneParacetamolPegfilgrastimPosaconazoleThiotepaTreosulfanUrsodeoxycholic acidValaciclovirSupportive substanceAllopurinolAnti-thymocyte Globulin (Rabbit)Balanced Crystalloid SolutionBusulfanCarmustineCiprofloxacinCotrimoxazoleDexamethasoneDimetindenEtoposide phosphateFilgrastimFluconazoleFludarabineFosaprepitantFurosemideGranisetronLevetiracetamMelphalanMesnaMethylprednisoloneParacetamolPegfilgrastimPosaconazoleThiotepaTreosulfanUrsodeoxycholic acidValaciclovirSupportive substanceAllopurinolAnti-thymocyte Globulin (Rabbit)Balanced Crystalloid SolutionBusulfanCarmustineCiprofloxacinCotrimoxazoleDexamethasoneDimetindenEtoposide phosphateFilgrastimFluconazoleFludarabineFosaprepitantFurosemideGranisetronLevetiracetamMelphalanMesnaMethylprednisoloneParacetamolPegfilgrastimPosaconazoleThiotepaTreosulfanUrsodeoxycholic acidValaciclovirSupportive substanceAllopurinolAnti-thymocyte Globulin (Rabbit)Balanced Crystalloid SolutionBusulfanCarmustineCiprofloxacinCotrimoxazoleDexamethasoneDimetindenEtoposide phosphateFilgrastimFluconazoleFludarabineFosaprepitantFurosemideGranisetronLevetiracetamMelphalanMesnaMethylprednisoloneParacetamolPegfilgrastimPosaconazoleThiotepaTreosulfanUrsodeoxycholic acidValaciclovirNo. Substances1235610111216Protocol classificationTherapy classificationalternativecurrent standardStudy protocol, currentIntensityKonditionierung, intensitäts- oder dosisreduziert (RIC)Konditionierung, myeloablativ (MAC)Low doseStandard doseTherapy indicationFirst lineRelapse therapyseveral possibleTherapy phaseallogene StammzelltransplantationConsolidationInductionMaintenanceTherapy intentioncurativecurative or palliativepalliativeRisksAnemia Hb below 8g/dlAstheniaBleedingCardiotoxicityColitisDiarrheaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaGastrointestinal ToxicityHepatotoxicityHyperbilirubinemiaHyperglycemiaHypokalemiaHyponatremiaHypophosphatemiaIncrease AminotransferasesInfectionsNeurotoxicityNeutropeniaPainPneumoniaRenal FailureSepsisThrombocytopenia below 50 000/µl only studiesPublicationAuthorBeelen DWBlume KGCiurea SOCortes JECraddock CDusenbery KEDöhner HEstey ELübbert MMarks RPlatzbecker URambaldi ASchroeder TShimoni AStone RStratmann JStölzel FDiseaseAML, 40-65 Jahre, ECOG 0-2, < 5% BlastenAML, MDS, CML, NHL, ungeeignet für konventionelle intensive KonditionierungAML, über 50 J.AML- oder CMML-Rezidiv nach allogener StammzelltranplantationAML- oder MDS-Rezidiv nach allogener StammzelltranplantationAML/ALL/CML, allogene StammzelltransplantationAML/MDS, 15-70 Jahre, mit HLA-identischem oder an einem Locus nicht übereinstimmender Geschwister-, Familien- oder nicht verwandtem SpenderAML/MDS, 18-65 Jahre, < 5% BlastenAML/MDS, 18-70 Jahre, AML in kompletter hämatologischer Remission (unter 5% Blasten) oder MDS (unter 20% Blasten), HCT-CI Score über 2AML/MDS, allogene StammzelltransplantationAML/MDS, ungeeignet für konventionelle intensive KonditionierungAML/MDS, unter 55 JahreAML oder Hochrisiko MDS, nicht für eine Standard-Induktionschemotherapie geeignet, ECOG 0-2de-novo oder sekundäre AML, mindestens 1 nicht-kurative Vortherapie, über 65 JahreDrohendes AML- oder MDS-Rezidiv nach allogener Stammzelltranplantation (Spenderchimärismus <80%)neudiagnostizierte AML, Erhaltung bei Patienten in kompletter Remission, FLT3-Mutation, ErstlinieNeu diagnostizierte AML oder MDS mit Blastenüberschuss-2, ECOG 0-2OriginAlbert-Ludwigs University Medical Center, Freiburg, GermanyCarl Gustav Carus Technical University of Dresden, Dresden, Germany, RELAZA trialCity of Hope National Medical Center, California, USADana-Farber Cancer Institute, Boston MADepartment of Haematology and Oncology, Albert-Ludwigs University Medical Center, FreiburgDepartment of Therapeutic Radiology, University of Minnesota Hospital and Clinics, MinneapolisDivision Hematology and Oncology, University of Freiburg Medical Center, Freiburg, GermanyHematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, ItalyHematology and Oncology, Goethe University, Frankfurt, Frankfurt am Main, GermanyOncology and Clinical Immunology, University of Duesseldorf, Medical Faculty, Duesseldorf, GermanyThe Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, IsraelThe University of Texas M. D. Anderson Cancer Center, Houston, USAUlm University Hospital, Germany, AMLSG 31-19/HOVON 501University Hospital Schleswig-Holstein, Kiel, Christian Albrechts University, Kiel, GermanyUniversity of Birmingham, Birmingham, United KingdomUniversity of Texas, MD Anderson Cancer Center, Houston, USAUniversity of Texas MD Anderson Cancer Center, Houston, USAWest German Cancer Centre, University of Duisburg-Essen, Essen, GermanyProtokolle in Überarbeitung 22 protocols foundAzacitidin 100, akute myeloische Leukämie und myelodysplastisches Syndrom nach allogener Stammzelltransplantation (PID2302 V1.0)Azacitidin 100, akute myeloische Leukämie und myelodysplastisches Syndrom nach allogener Stammzelltransplantation, Variante 1 (PID2320 V1.0)Azacitidin 75 / Lenalidomid 25, akute myeloische Leukämie und myelodysplastisches Syndrom nach allogener Stammzelltransplantation (PID827 V1.2)Azacitidin 75, akute myeloische Leukämie und myelodysplastisches Syndrom nach allogener Stammzelltransplantation (PID2327 V1.0)Cyclophosphamid 60 / TBI 13,2, allogene Stammzelltransplantation, MAC (PID3218 V1.0)Cytarabine 20 / Glasdegib 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome (PID1674 V1.0)Etoposidphosphat 60 / TBI 13,2, allogene Stammzelltransplantation, MAC (PID3221 V1.0)Fludarabine 30 / Busulfan 3.2, Acute Myeloid Leukemia, Stem Cell Transplantation, Allogeneic (PID3226 V1.0)Fludarabin 30 / Carmustin 150 / Melphalan 110, allogene Stammzelltransplantation, RIC (PID880 V1.0)Fludarabin 30 / Carmustin 200 / Melphalan 140, akute myeloische Leukämie und myelodysplastisches Syndrom, allogene Stammzelltransplantation, RIC (PID1705 V1.0)Fludarabin 30 / Melphalan 100, akute myeloische Leukämie und myelodysplastisches Syndrom, allogene Stammzelltransplantation, RIC (PID3225 V1.0)Fludarabin 30 / Treosulfan 10, akute myeloische Leukämie und myelodysplastisches Syndrom, allogene Stammzelltransplantation, MAC (PID1706 V1.0)Fludarabine 40 / Busulfan 0.8 / Anti-thymocyte Globulin (Rabbit) (0.5/2.0/2.5), Acute Myeloid Leukemia, Allogeneic Stem Cell Transplantation, MAC (PID885 V1.0)Fludarabin 40 / Busulfan 3,2 / Antithymozytenglobulin vom Kaninchen 10, akute myeloische Leukämie und myelodysplastisches Syndrom, allogene Stammzelltransplantation, MAC (PID881 V1.0)Melphalan 140 / Thiotepa 10 / Fludarabin 40, akute myeloische Leukämie und myelodysplastisches Syndrom, allogene Stammzelltransplantation, RIC (PID1738 V1.0)Melphalan 2, Acute Myeloid Leukemia, over 65 years of age (PID1735 V1.1)Midostaurin 50, Acute Myeloid Leukemia, maintenance (PID1081 V1.1)Study-AMLSG 31-19/HOVON 501 - Cytarabine 1000 / Venetoclax 400, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Induction II, over 60 years of age (PID3142 V1.0)Study-AMLSG 31-19/HOVON 501 - Cytarabine 1000 / Venetoclax 400, Acute Myeloid Leukemia and Myelodysplastic Syndrome, consolidation, over 60 years of age (PID3144 V1.0)Study-AMLSG 31-19/HOVON 501 - Cytarabine 1500 / Venetoclax 400, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Consolidation, under 60 years of age (PID3143 V1.0)Study-AMLSG 31-19/HOVON 501 - Daunorubicin 60 / Cytarabine 1000 / Venetoclax 400, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Induction II, under 60 years of age (PID3141 V1.0)Study-AMLSG 31-19/HOVON 501 - Daunorubicin 60 / Cytarabine 200 / Venetoclax (100/200/400), Acute Myeloid Leukemia and Myelodysplastic Syndrome, Induction I (PID3140 V1.0)
